Annual Drug Patent Expirations for HYSINGLA+ER
Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are twenty-three patents protecting this drug and two Paragraph IV challenges.
HYSINGLA ER drug price trends.
Drug patent litigation for HYSINGLA ER.
This drug has three hundred and ninety-seven patent family members in forty-nine countries.
The generic ingredient in HYSINGLA ER is hydrocodone bitartrate. One supplier is listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
